Curis shifts focus to later-stage drug development, appoints new chief scientific officer

By Elaine Rigoli

Tampa, Fla., June 8 - Curis, Inc. said Thursday it has started a new strategic focus seeking to develop later-stage drug-development programs and to de-emphasize its earlier-stage discovery research.

"As Curis executes on its efforts to move closer to the clinic with its preclinical drug candidates, over the next year, we intend to shift our strategic focus away from early stage discovery research into later-preclinical stage drug development. As part of this transition and aligned with this strategy, Dr. Lee Rubin, our executive vice president and chief scientific officer, will step down as Curis' CSO, having accepted a position at the Harvard University Stem Cell Institute," president and chief executive officer Daniel R. Passeri said in a news release.

Current board member Joseph Davie will serve as interim chief scientific officer and will temporarily oversee Curis' drug programs while also assisting Curis in its efforts to build a more development-focused scientific team.

Curis is a therapeutic drug-development company located in Cambridge, Mass.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.